Back to Newsroom

Data from Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society

BOTHELL, Wash., June 26, 2014 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King’s College London and director, Headache Center, Department of Neurology, University of California, San Francisco, and David W. Dodick, M.D., professor of neurology at the Mayo Clinic, will present results from a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial of ALD403 for the prevention of frequent episodic migraine at the 56th Annual Scientific Meeting of the American Headache Society at the Hyatt Regency Century Plaza in Los Angeles, California.

Click here to read more